B

Braidwell Portfolio holdings

AUM $2.7B Turnover 43.12%
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+5.48%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.53B
AUM Growth
+$340M
Cap. Flow
-$901M
Cap. Flow %
-25.54%
Top 10 Hldgs %
34.64%
Holding
89
New
15
Increased
24
Reduced
22
Closed
8
Avg Time Held
0.8 years
Top 10 Avg Time Held
0.9 years
Top 20 Avg Time Held
0.7 years

Top Buys

Rank Stock Value
1
APLS icon
Apellis Pharmaceuticals
APLS
+$93.1M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$47M
3
BCAX icon
Bicara Therapeutics
BCAX
+$42.3M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$39.9M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$39M

Top Sells

Rank Stock Value
1
EXAS icon
Exact Sciences
EXAS
+$48.3M
2
PCVX icon
Vaxcyte
PCVX
+$46M
3
TMO icon
Thermo Fisher Scientific
TMO
+$39M
4
APGE icon
Apogee Therapeutics
APGE
+$35.9M
5
ARGX icon
argenx
ARGX
+$35.5M

Sector Composition

Rank Sector Weight
1 Healthcare 65.68%
2 Miscellaneous 34.16%
3 Consumer Staples 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
MDGL icon
26
Madrigal Pharmaceuticals
MDGL
$10.6B
$39M 1.11%
+183,818
New +$47M
2024 Q3
0 quarters
PCVX icon
27
Vaxcyte
PCVX
$10.6B
$34M 0.96%
297,568
-510,735
-63% -$46M
2022 Q4
7 quarters
REPL icon
28
Replimune Group
REPL
$1.07B
$33.7M 0.95%
3,070,837
+2,057,460
+203% +$20.9M
2024 Q2
1 quarter
ARVN icon
29
Arvinas
ARVN
$446M
$31.6M 0.9%
1,284,472
+767,242
+148% +$20M
2024 Q2
1 quarter
KRYS icon
30
Krystal Biotech
KRYS
$9.79B
$30.7M 0.87%
168,691
+61,512
+57% +$11.9M
2022 Q4
7 quarters
KIDS icon
31
OrthoPediatrics
KIDS
$581M
$30M 0.85%
1,107,770
– –
2022 Q4
7 quarters
DXCM icon
32
DexCom
DXCM
$31.5B
$29.6M 0.84%
+441,086
New +$36.2M
2024 Q3
0 quarters
BNTX icon
33
BioNTech
BNTX
$22.3B
$29.4M 0.83%
+247,750
New +$22.8M
2024 Q3
0 quarters
FNA icon
34
DELISTED
Paragon 28, Inc.
FNA
$27.6M 0.78%
4,135,109
-15,000
-0.4% -$114K
2023 Q1
6 quarters
RLAY icon
35
Relay Therapeutics
RLAY
$3.74B
$24.8M 0.7%
3,499,427
+492,628
+16% +$3.68M
2024 Q1
2 quarters
ATEC icon
36
Alphatec Holdings
ATEC
$1.61B
$22.5M 0.64%
4,041,065
+1,846,165
+84% +$14.2M
2024 Q2
1 quarter
HROW icon
37
Harrow
HROW
$1.02B
$19.8M 0.56%
439,638
+142,450
+48% +$4.82M
2023 Q1
6 quarters
CGEM icon
38
Cullinan Oncology
CGEM
$878M
$19.7M 0.56%
1,176,173
+1,000,000
+568% +$17.7M
2023 Q2
5 quarters
EXAS icon
39
DELISTED
Exact Sciences
EXAS
$19.5M 0.55%
286,178
-855,500
-75% -$48.3M
2024 Q2
1 quarter
OCUL icon
40
Ocular Therapeutix
OCUL
$1.58B
$19.5M 0.55%
2,239,770
+596,000
+36% +$4.91M
2024 Q2
1 quarter
IMTX icon
41
Immatics
IMTX
$1.07B
$18.8M 0.53%
+1,647,565
New +$19.5M
2024 Q3
0 quarters
IRWD icon
42
Ironwood Pharmaceuticals
IRWD
$595M
$18.3M 0.52%
4,438,232
– –
2024 Q1
2 quarters
BSX icon
43
Boston Scientific
BSX
$62.3B
$15.9M 0.45%
+189,200
New +$14.9M
2024 Q3
0 quarters
DNTH icon
44
Dianthus Therapeutics
DNTH
$4.18B
$13.5M 0.38%
493,687
+126,836
+35% +$3.53M
2024 Q2
1 quarter
FDMT icon
45
4D Molecular Therapeutics
FDMT
$674M
$13.2M 0.38%
1,225,448
+855,990
+232% +$14.2M
2024 Q1
2 quarters
CELC icon
46
Celcuity
CELC
$2.93B
$13.2M 0.37%
884,306
+367,663
+71% +$6.06M
2024 Q2
1 quarter
ORKA icon
47
Oruka Therapeutics
ORKA
$5.08B
$12.6M 0.36%
+515,726
New +$17.9M
2024 Q3
0 quarters
ALEC icon
48
Alector
ALEC
$210M
$10.1M 0.29%
2,158,245
-222,459
-9% -$1.19M
2022 Q4
7 quarters
ZURA icon
49
Zura Bio
ZURA
$423M
$10M 0.28%
+2,472,806
New +$9.24M
2024 Q3
0 quarters
PODD icon
50
Insulet
PODD
$9.29B
$9.89M 0.28%
+42,500
New +$8.73M
2024 Q3
0 quarters
1
2
3

Similar funds

M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $2.72B AUM
SCM
Steele Capital Management Dubuque, Iowa $2.72B AUM 21.58% 1-Year Est. Return

Braidwell's Q3 2024 Portfolio in Review

As of Q3 2024, Braidwell held 89 positions worth $3.53B, up 11% from $3.19B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Braidwell withdrew a net $901M in Q3 2024, closing 8 positions and reducing 22 holdings. Its most notable exit was Thermo Fisher Scientific, an estimated $39M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 61% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Braidwell opened a new position in Madrigal Pharmaceuticals worth $39M.

  • Braidwell's largest Q3 2024 buy was Madrigal Pharmaceuticals: 183,818 shares worth $39M.
  • Braidwell added most to Apellis Pharmaceuticals in Q3 2024, an estimated $93.1M increase.
  • Braidwell's biggest Q3 2024 reduction was Exact Sciences, cutting an estimated $48.3M.
  • Braidwell fully exited Thermo Fisher Scientific in Q3 2024, selling an estimated $39M.
  • Braidwell's ten largest holdings make up 35% of its $3.53B portfolio in Q3 2024.
  • Braidwell opened 15 new positions and closed 8 in Q3 2024.
  • Braidwell's portfolio value rose 11% quarter-over-quarter to $3.53B.

Based on Braidwell's 13F filing for Q3 2024, filed 14 Nov 2024.